Form 4: Ionis Pharmaceuticals Executive Stock Sale

EVP and Chief Development Officer Holly Kordasiewicz exercised stock options and sold 60,846 shares of Ionis Pharmaceuticals.

Summary

• Holly Kordasiewicz, EVP and Chief Development Officer of Ionis Pharmaceuticals, exercised options to acquire 60,846 shares of common stock.
• The exercise prices for these options ranged from $32.60 to $60.89 per share.
• Following the acquisition, the executive sold 60,846 shares in two tranches at weighted average prices of $73.09 and $74.05.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it is an insider sale, it was executed via a pre-planned 10b5-1 program, which is standard corporate practice.

Positives

• The executive maintains a remaining beneficial ownership of 22,458 shares of common stock.
• The sale was conducted under a pre-arranged Rule 10b5-1 plan, which typically indicates a systematic approach to liquidity rather than reactive trading.

Negatives

• The transaction represents a significant divestment of equity by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived by the market as a signal that management believes the stock price is near its near-term peak.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales are common in the biotechnology sector, often occurring as part of scheduled compensation realization or tax planning under 10b5-1 plans.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is standard practice for corporate insiders to avoid potential conflicts of interest or accusations of insider trading.
• The volume of shares sold is consistent with typical executive compensation liquidation patterns for a company of Ionis Pharmaceuticals' market capitalization.

Stakeholder Impact

• Shareholders should note the reduction in the executive's direct equity stake, though the remaining holdings indicate continued alignment with company performance.

Next Steps

• No future corporate actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Biotech